SCHEMBL17216504

SCHEMBL17216504

CCC/[C]=N/OCc1ccccc1C(F)(F)F

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.49
MAOB P27338 4/20 0.41
MAOA P21397 1/20 0.41
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 3/20 0.36
CARM1 Q86X55 1/20 0.36
PRMT6 Q96LA8 1/20 0.36
TACR1 P25103 1/20 0.35
FFAR1 O14842 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
POLQ O75417 1/20 0.34
AR P10275 1/20 0.34
F2 P00734 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
KDM4E B2RXH2 2/20 0.33
ALDH1A1 P00352 2/20 0.33
ATM Q13315 1/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17216508 1.00 IDO1 (0.49) IDO1MAOBMAOASLC6A2SLC6A4
SCHEMBL17218464 0.92 IDO1 (0.46) IDO1MAOBMAOASLC6A2SLC6A4
SCHEMBL17218467 0.92 IDO1 (0.46) IDO1MAOBMAOASLC6A2SLC6A4
SCHEMBL17218837 0.88 IDO1 (0.51) IDO1MAOBMAOASLC6A2SLC6A4
SCHEMBL17218839 0.88 IDO1 (0.51) IDO1MAOBMAOASLC6A2SLC6A4
SCHEMBL17986309 0.81 IDO1 (0.54) IDO1MAOBMAOACARM1PRMT6
SCHEMBL17986307 0.81 IDO1 (0.54) IDO1MAOBMAOACARM1PRMT6
SCHEMBL17218601 0.80 IDO1 (0.44) IDO1MAOBKDM4EALDH1A1
SCHEMBL17218603 0.80 IDO1 (0.44) IDO1MAOBKDM4EALDH1A1
SCHEMBL17216314 0.80 SLC6A3 (0.37) SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 EP disclosed
US-9635857-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-02 US disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 US disclosed
US-20160235065-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2016-08-18 US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235065-A1 TETRAZOLINONE COMPOUND AND USE THEREOF MRPS17, TAOK1, TAOK3 IDO1 1822/4885MAOB 2207/4885MAOA 1844/4885
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 IDO1 2882/4885MAOB 3611/4885MAOA 3360/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.